Nasal mucosal administration of chitin microparticles boosts innate immunity against influenza A virus in the local pulmonary tissue

Abstract Influenza virus infection remains a major health concern due to morbidity and mortality associated with epidemics and occasional pandemics. The absence of acquired immunity to antigenically distinct, emerging virus strains stresses the need for a generic drug that protects independent of va...

Full description

Saved in:
Bibliographic Details
Published in:Vaccine 2010-06, Vol.28 (25), p.4130-4137
Main Authors: Baaten, B.J.G, Clarke, B, Strong, P, Hou, S
Format: Article
Language:English
Subjects:
Administration, Intranasal
Allergy and Immunology
Animals
Applied microbiology
Biological and medical sciences
Chitin
Chitin - immunology
Chitin microparticles
Cytokines - immunology
Female
Fundamental and applied biological sciences. Psychology
Immune response
Immune system
Immunity, Innate
Infections
Influenza
Influenza A virus
Influenza A virus - immunology
Influenza Vaccines - immunology
Influenza virus
Lung - immunology
Lung - virology
Mice
Mice, Inbred C57BL
Microbiology
Miscellaneous
Neutrophil
Neutrophils - immunology
Orthomyxoviridae Infections - immunology
Orthomyxoviridae Infections - prevention & control
Pandemics
Rodents
T-Lymphocytes - immunology
Vaccines
Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects)
Viral Load
Virology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Influenza virus infection remains a major health concern due to morbidity and mortality associated with epidemics and occasional pandemics. The absence of acquired immunity to antigenically distinct, emerging virus strains stresses the need for a generic drug that protects independent of vaccination. Here, we demonstrate that prophylactic administration of chitin microparticles (CMP) via the intranasal route significantly reduced lung viral titres and clinical signs. Pre-treatment boosted the innate immune response to subsequent infection by recruiting innate cells, such as neutrophils, and increasing inflammatory cytokines. Although an increase in virus-specific T cells was observed, the memory phase was diminished. Our data demonstrate that in the absence of prior exposure to influenza virus, CMP reduce clinical signs by boosting innate immunity.
ISSN:0264-410X
1873-2518
DOI:10.1016/j.vaccine.2010.04.026